Apr 4
|
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 19
|
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
|
Mar 12
|
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
|
Mar 9
|
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
|
Mar 5
|
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
|
Jan 8
|
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
|
Jan 3
|
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 4
|
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
|
Dec 4
|
After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain
|
Dec 2
|
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
|
Nov 30
|
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
|
Nov 29
|
Xenon Pharmaceuticals Announces Proposed Public Offering
|
Nov 28
|
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
|
Nov 27
|
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
|
Nov 27
|
UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study
|
Nov 27
|
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
|
Nov 27
|
Xenon drug misses main goal of depression study
|
Nov 9
|
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript
|
Nov 9
|
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
|
Nov 8
|
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|